Claims
- 1. An antisense oligonucleotide which is targeted to an mRNA encoding human intercellular adhesion molecule-1, and which inhibits the expression of said human intercellular adhesion molecule-1 with the proviso that the antisense oligonucleotide does not consist of SEO ID NO: 84.
- 2. The antisense oligonucleotide of claim 1 which comprises at least one 2'-O-methoxyethyl modification.
- 3. The antisense oligonucleotide of claim 1 which has SEQ ID NO: 86, 87, 89, 91, 92, 93, 94, 95, 97, 98, 99, 100, 101, 102, 103 or 105.
- 4. A pharmaceutical composition comprising the antisense oligonucleotide of claim 3.
- 5. The pharmaceutical composition of claim 4 further comprising one or more of the following: saline, a colloidal dispersion system, a liposome, an emulsion, a cream or a penetration enhancer.
- 6. The pharmaceutical composition of claim 3 comprising SEQ ID NO: 22.
- 7. A method of modulating the synthesis of human intercellular adhesion molecule-1 comprising contacting a nucleic acid encoding said human intercellular adhesion molecule-1 with an antisense oligonucleotide of claim 1.
- 8. The method of claim 7 wherein said antisense oligonucleotide has SEQ ID NO: 22.
- 9. A method of treating an animal having a disease or condition selected from the group consisting of: inflammatory bowel disease, colitis, Crohn's disease, psoriasis, cytotoxic dermatitis, ulcerative colitis, and rheumatoid arthritis, comprising administering to said animal a prophylactic or therapeutic amount of the antisense oligonucleotide claim 1 whereby said disease or condition is prevented or treated.
- 10. The method of claim 9 wherein the antisense oligonucleotide is formulated in a pharmaceutical composition comprising one or more of the following: saline, a colloidal dispersion system, a liposome, an emulsion, a cream or a penetration enhancer.
- 11. The method of claim 9 wherein said animal is a human and the antisense oligonucleotide is targeted to human intercellular adhesion molecule-1.
- 12. The method of claim 11 wherein said disease or condition is a disease or condition of the skin.
- 13. The method of claim 12 wherein said disease or condition of the skin is psoriasis or cytotoxic dermatitis.
- 14. The method of claim 11 wherein said disease or condition is rheumatoid arthritis.
- 15. The method of claim 9 wherein said disease is pneumonia or multiple sclerosis.
- 16. The method of claim 11 wherein said antisense oligonucleotide has SEQ ID NO: 22.
- 17. The method of claim 9 wherein the disease or condition is an inflammatory disease or condition.
- 18. The method of claim 17 wherein said disease or condition is inflammatory bowel disease.
- 19. The method of claim 9 wherein said inflammatory bowel disease is Crohn's disease, colitis or ulcerative colitis.
- 20. A method of reducing corticosteroid use in a patient to whom corticosteroids are being administered or are likely to be administered comprising administering to said patient a therapeutically or prophylactically effective amount of an antisense oligonucleotide of claim 1.
- 21. The method of claim 20 wherein the patient has, is suspected of having or is prone to an inflammatory condition.
- 22. The method of claim 21 wherein the inflammatory condition is inflammatory bowel disease and the antisense oligonucleotide has SEQ ID NO: 22.
CROSS-REFERENCES TO RELATED APPLICATIONS
This application is a continuation-in-part of application Ser. No. 08/440,740 (filed May 12, 1995, now U.S. Pat. No. 5,843,738), which is a continuation-in-part of application Ser. No. 08/063,167 (filed May 17, 1993, now U.S. Pat. No. 5,514,788) which is a continuation of application Ser. No. 07/969,151 (filed Feb. 10, 1993), now abandoned, which is a continuation-in-part of application Ser. No. 08/007,997 (filed Jan. 21, 1993, now U.S. Pat. No. 5,591,623), which is a continuation-in-part of application Ser. No. 07/939,855 (filed Sep. 2, 1992), now abandoned, which is a continuation-in-part of application Ser. No. 07/567,286 (filed Aug. 14, 1990), now abandoned. The contents of all of the aforementioned are herein incorporated by reference in their entirety.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
5514788 |
Bennett et al. |
May 1996 |
|
5591623 |
Bennett et al. |
Jan 1997 |
|
5789573 |
Baker et al. |
Aug 1998 |
|
5843738 |
Bennett et al. |
Dec 1998 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
WO 9116900 |
Nov 1991 |
WOX |
Non-Patent Literature Citations (8)
Entry |
Andrea D. Branch, A good antisense molecule is hard to find, TIBS, 47-48, Feb. 1998. |
Trisha Gura, Antisense Has Growing Pains, Science, pp. 575-577, Oct. 1995. |
Stanley Crooke, Antisense '97: A roundtable on the state of the industry, Nature Biotechnology, p. 522, Jun. 1997. |
Stanley Crooke, Antisense Research and Applications, Chapter 1, Basic Principles of Antisense Therapeutics, Springer-Verlag Press, Berlin, Heidelberg, New York, p. 3, Jul. 1998. |
Wegner et al., "Intercellular Adhesion Molecule-1 (ICAM-1) in the Pathogenesis of Asthma", Science 1990, 247, 456-459. |
Cosimi et al., "In Vivo Effects of Monoclonal Antibody To ICAN-1 (CD54) In Nonhuman Primates With Renal Allografts .sup.1 ", J. Immunol. 1990 144, 4604-4612. |
Isobe et al., "Specific Acceptance of Cardiac Allograft After Treatment with Antibodies to ICAM-1 and LFA-1", Science 1992, 255, 1125-1127. |
Marlin, et al., "A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection", Nature 1990, 344, 70-72. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
969151 |
Feb 1993 |
|
Continuation in Parts (5)
|
Number |
Date |
Country |
Parent |
440740 |
May 1995 |
|
Parent |
063167 |
May 1993 |
|
Parent |
007997 |
Jan 1993 |
|
Parent |
939855 |
Sep 1992 |
|
Parent |
567286 |
Aug 1990 |
|